Troutman Pepper Hamilton Sanders advised Palvella Therapeutics, Inc. on the deal. Palvella Therapeutics, Inc., a late clinical-stage biopharmaceutical company, announced the initial closing of its Series...
Palvella Therapeutics’ Series D Financing
iECURE’s $65 Million Series A-1 Financing
Troutman Pepper advised iECURE on the deal. iECURE, a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies...
Center for Breakthrough Medicines’ Partnership with University of Pennsylvania
Troutman Pepper advised Center for Breakthrough Medicines on the deal. Center for Breakthrough Medicines (CBM) has struck a landmark collaboration agreement with the University of Pennsylvania’s...
SK Group’s $350 Million Investment in The Center for Breakthrough Medicines
Simpson Thacher represented SK Group on the deal while Troutman Pepper Hamilton Sanders advised Center for Breakthrough Medicines. SK Inc. announced its $350 million investment in The...